Eli Lilly LLY recently announced that it has entered into a definitive agreement to acquire the privately held clinical-stage company SiteOne Therapeutics in a deal valued at $1 billion. Through ...

Eli Lilly and Company’s LLY stock has declined 15.7% in the past year. The first-quarter earnings miss, guidance cut and some ...

Transaction will augment Lilly's efforts to advance non-opioid medicines for pain management. INDIANAPOLIS, May 27, 2025 /PRNewswire/ -- Eli Lilly and Company and SiteOne Therapeutics, Inc ...

On Wednesday, BMO Capital maintained its Outperform rating on Eli Lilly stock (NYSE: LLY), coupled with a steadfast price target of $900.00.With analyst targets ranging from $650 to $1,190 and a ...

Eli Lilly & Co. agreed to buy gene-editing biotech company Verve Therapeutics Inc. for $1.3 ... Lilly will pay as much as $13.50 per ... it announced a plan to buy SiteOne Therapeutics Inc., ...

Eli Lilly has agreed to acquire privately held biopharma company SiteOne Therapeutics, adding a non-opioid-based pain treatment to the big pharma’s pipeline. The sale agreement will see Eli ...

Transaction will augment Lilly's efforts to advance non-opioid medicines for pain management INDIANAPOLIS, May 27, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and SiteOne Therapeutics ...

Eli Lilly LLY recently announced that it has entered into a definitive agreement to acquire the privately held clinical-stage company SiteOne Therapeutics in a deal valued at $1 billion.. Through this ...

Transaction will augment Lilly's efforts to advance non-opioid medicines for pain management INDIANAPOLIS, May 27, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and SiteOne Therapeutics ...

INDIANAPOLIS, May 27, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and SiteOne Therapeutics, Inc. ("SiteOne"), a private biotechnology company developing small molecule inhibitors of ...